Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jaguar Animal Health (JAGX)
NASDAQ:JAGX
Holding JAGX?
Track your performance easily
Earnings Data
Report Date
Apr 15, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: -15.14%
|Next Earnings Date:Apr 15, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and promising clinical trial results, particularly in the area of cancer treatment. However, the company's increased net loss and non-GAAP recurring EBITDA loss indicate financial challenges. The achievements in drug development and product launches suggest potential future growth, but financial improvements are necessary.Company Guidance
During the Q3 2024 earnings call for Jaguar Health, the company reported a net revenue of approximately $3.1 million, marking a 14% increase from Q2 2024 and an 11% increase from Q3 2023. The call highlighted the company's ongoing efforts in commercial and development initiatives, including the launch of their third FDA-approved prescription product, Gelclair, in the U.S. Additionally, significant results from the Phase III OnTarget trial in breast cancer patients will be presented at the San Antonio Breast Cancer Symposium. The company is also advancing clinical trials for crofelemer in rare disease indications such as microvillous inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF), with Phase II trials expected to start in Q4 2024. Financially, the company's net loss from operations reduced from $8.8 million in Q3 2023 to $7.3 million in Q3 2024, while non-GAAP recurring EBITDA showed a loss of $9.2 million. The board has no intention of implementing a reverse stock split, focusing instead on upcoming catalysts and strategic developments.Revenue Growth
Net third quarter 2024 revenue was approximately $3.1 million, which represents a 14% increase over the second quarter of 2024 and an 11% increase over the third quarter of 2023.
Phase III OnTarget Trial Success
Significant results achieved in the Phase III OnTarget trial for breast cancer patients, with results accepted for presentation at the San Antonio Breast Cancer Symposium.
Gelclair Launch
Launch of FDA-approved oral mucositis prescription product, Gelclair, in the United States, aimed at managing cancer treatment-related side effects.
Orphan Drug Designations
Crofelemer received orphan drug designation in the United States and Europe for MVID and SBS-IF indications.
---
JAGX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JAGX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $1.09 | $0.99 | -9.17% |
| Aug 13, 2024 | $1.20 | $1.07 | -10.83% |
| May 14, 2024 | $17.42 | $16.49 | -5.34% |
| Apr 01, 2024 | $5.39 | $4.62 | -14.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Jaguar Animal Health (JAGX) report earnings?
Jaguar Animal Health (JAGX) is schdueled to report earning on Apr 15, 2025, TBA Not Confirmed.
What is Jaguar Animal Health (JAGX) earnings time?
Jaguar Animal Health (JAGX) earnings time is at Apr 15, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JAGX EPS forecast?
Currently, no data Available
---